|
Jean-Pierre Boissel is the co-founder and Chief Scientific Officer of Novadiscovery. Jean-Pierre is an internationally recognized researcher in the field of therapeutic evaluation, cardiology and systems medicine. Emeritus Professor of Clinical Pharmacology, he is considered one of the founding fathers of systems medicine alongside Prof. Leroy Hood (US), Prof. Denis Noble (UK) and Prof. Charles Auffray (France). ==History== Author of over 300 articles in peer-reviewed journals, Jean-Pierre has, throughout his career, formulated and contributed to the implementation of innovative solutions to many a scientific and methodological hurdle healthcare players are customarily faced with. In the 70s, he designed and directed the first randomized multicenter clinical trial with a control group in France in cardiology for the assessment of aspirin in secondary prevention.〔The EPSIM Research Group. Controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. NEJM 1982;307:701-8〕 During the same period, he sets up the first European lab mastering animal and human arterial smooth muscle cell line culture.〔Boissel JP, Bourdillon MC, Loire R, Crouzet B. Histological arguments for collagen and elastin synthesis by primary cultures of rat aortic media cells. Atherosclerosis 1976;25:107-10〕 A decade later, he convinces Jacques Delors, then President of the European Commission, to fund a clinical trial of early thrombolysis in patients suspected to develop an acute myocardial infarction, at home or in the ambulance. He gets the USSR to participate in this trial, which will be a double first: the first randomized double blind clinical trial supported by the European Commission and the first in the USSR. Among the innovations applied during this trial, a mini-“computer” used onboard ambulances to enable randomization of and allocation of compared treatments to patients.〔The EMIP Group. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. NEJM 1993:329:383-9〕 With the emergence of the French “Minitel” in the 80s, he uses this tool to capture and control on-site data collected by physicians involved in clinical trials.〔Moleur P, Peyrieux JC, Luciani J, David D, Boissel JP and the Practitioners of the French Bopindolol Study Group. Bopindolol in the treatment of moderate hypertension: a dose-response study. Fundam Clin Pharmacol 1988;2:431-40.〕 He directly contributes to the establishment of the standard in methodological design and implementation of clinical trials, pushing for the establishment of double blind randomized trials with control groups as the gold standard.〔Boissel JP, Biron A, Leizorovicz A, Deguerry C. PROGET: A large scale cooperative trial computerized management system. In: IEEE/Computers in Cardiology. Hugenholtz PH, Cox DR Eds. Long Beach 1977:127-35.〕 Faced with the exponential increase in biomedical knowledge, he proves existing systems to transfer knowledge from bench to bedside wholly inadequate. He publishes the first French work in this area in 1980, funded by INSERM.〔Boissel JP, Ferry S, Gallois P. Use of sales statistics for evaluating prescription rationale. TIPS 1983;4:401-4.〕〔Boissel JP. Impact of randomized clinical trials on medical practices. Control Clin Trials 1989;10:120S-134S.〕 He therefore researches methodological approaches to address this issue. On the subject of knowledge transfer, well before the term "translational" research was coined, he sets up and leads a European project funded by DG XII.〔Boissel JP, on behalf of the Validata Group. Europe: Computerised information for prescribers. Lancet 1991;338:1513-4〕 He summarizes the results of this work in a collaborative book called "Information thérapeutique",〔Boissel J-P, Bossard N, Cucherat M, Haugh MC, Fardeheb M, Rachet F, et al. L’information thérapeutique. Masson; 2000.〕 which lays the foundations for personalized medicine. One of the pioneers in meta-analyses to evaluate therapeutic efficacy, he is the first to demonstrate the efficacy of an anti-aggregating agent, ticlopidine, to prevent clinical events with patients suffering from lower-limb atherosclerosis.〔Boissel JP, Peyrieux JC, Destors JM. Is it possible to reduce the risk of cardio-vascular events in subjects suffering from intermittent claudication of the lower limbs? Thromb Haemost 1989;62:681-5〕 This demonstration will pave the way for the development of clopidogrel by the French pharmaceutical company Sanofi. He is approached in the late 80s by the French Ministry of Research to "spin off" a portion of his academic research unit, well before the creation of technology transfer offices. The resulting company, (RCTs SA ), is the first academic spinoff in France and one of the first CROs in Europe. RTCs currently employs forty full-time employees. In 1999, he is appointed Chief Scientific Officer to the Director General of the National Institute of Health and Medical Research (Inserm), responsible for Therapeutic Research, a position he holds until 2001. He then becomes special advisor to the new Head of Inserm and focuses on rare diseases, clinical trials and biological resources centers. During his time with Inserm, he launches several programs with the support of the CNRS and the French Ministry of Research, including one designed to identify tools created by researchers for their needs and that could be industrialized. He is also advisor to the Director of Health from 1995 to 1998. He represents France at the European Commission during the preparatory sessions of the (5th Framework Program for Research and Development ). He is also president of the "Quality of Life and Living Resources Program Impact Committee", European Commission (1999-2003). From 2004 to 2011, he is a member of the Public Health Impact group at the French “Haute Autorité de Santé” (HAS). He founds a second company in 1998, (ClinInfo ), which provides data management solutions for clinical trials. The company currently has a dozen employees and a branch in the US. In the 90s, confronted with the ever-decreasing number of new drugs introduced on the market at a time when biomedical knowledge produced and widely available in the scientific literature grows at an exponential pace, Jean-Pierre decides to address the central question of the productivity of pharmaceutical R&D. He makes the assumption that only the formal mathematical language can ensure the optimal use of available knowledge to describe the different biological mechanisms involved in the development and treatment of a disease. He discovers the Effect Model law, which is central to the approach developed by Novadiscovery. In 2004 he founds the (Institute for Theoretical Medicine ) to lay the conceptual foundations for what he calls systems pathophysiology, an extension on systems biology, which incorporates all the levels of life organization from genes to populations. He has also been involved in the management of ethical issues in medicine and medical research. He has been active in several ethical boards. He fostered the concept of registration of clinical trials.〔Boissel JP, Haugh MC. Clinical trial registries and ethics review boards: the results of a survey by the FICHTRE project. Fundam Clin Pharmacol 1997;11:281-4〕 Since 2009, he chairs the International Agency for Research on Cancer (IARC) Ethical Committee. Jean-Pierre has also been policy representative for the French Ministry of Foreign Affairs in Iran, Afghanistan and Bolivia. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Jean-Pierre Boissel」の詳細全文を読む スポンサード リンク
|